Le Lézard
Classified in: Transportation, Science and technology
Subject: ACC

Autoliv Retires Repurchased Shares, Decreases Number of Issued Shares


STOCKHOLM, March 28, 2024 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, today announced that as of March 28, 2024, the total number of issued shares of common stock is 86,126,221 of which 81,373,679 shares are outstanding. 

Autoliv retired 1,370,057 shares of common stock that had been repurchased during the quarter which resulted in a decrease in the issued shares.

The Company now has a total of 86,126,221 issued shares of common stock of which 81,373,679 shares are outstanding. Each share of outstanding common stock is entitled to one vote. After the retirement of the repurchased shares, Autoliv holds 4,752,542 shares of common stock in treasury which have no voting rights or rights to participate in distributions under Delaware law.

This information is of such character that Autoliv, Inc. is obliged to disclose in accordance with the Swedish Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med finansiella instrument). The information was distributed for disclosure, through the agency of the contact persons set out below, on March 28, 2024, 10:45 CET.

Inquiries: 

Media: Gabriella Etemad, Tel +46 (70) 612 64 24
Investors & Analysts: Anders Trapp, Tel +46 (0)8 587 206 71
Investors & Analysts: Henrik Kaar, Tel +46 (0)8 587 206 14

About Autoliv

Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world as well as mobility safety solutions, such as pedestrian protection, connected safety services and safety solutions for riders of powered two wheelers. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2023, our products saved  35,000 lives and reduced more than 450,000 injuries.

Our 70,000 associates in 25 countries are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. We drive innovation, research, and development at our 14 technical centers, with their 20 test tracks. Sales in 2023 amounted to $10.5 billion. For more information go to www.autoliv.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/autoliv/r/autoliv-retires-repurchased-shares--decreases-number-of-issued-shares,c3954244

The following files are available for download:

https://mb.cision.com/Main/751/3954244/2702985.pdf

Release

 

SOURCE Autoliv


These press releases may also interest you

at 00:45
Claudio Bono, Managing Director for two independent Hotels in Silicon Valley, is thrilled to unveil a groundbreaking platform and an idea that will transform the landscape of the urgent unhoused crisis and social issues. Leveraging his extensive...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Side Protocol with the OKX Wallet. Side Protocol is a cross-chain middleware protocol designed to enable seamless communication and asset transfer between heterogeneous...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...

26 avr 2024
The report titled "Cognitive Security Market by Component (Services, Solutions), Security Type (Application, Cloud, Cybersecurity), Application, Deployment Mode, Enterprise Type, Vertical - Global Forecast 2024-2030" is now available on...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...



News published on and distributed by: